ArticleScientific reports2019
A zebrafish drug screening platform boosts the discovery of novel therapeutics for spinal cord injury in mammals.
Article in Scientific reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 28 citations in OpenAlex.
- Zebrafish as an Integrative Model for Central Nervous System Research: Current Advances and Translational Perspectives.Life (Basel, Switzerland) · 2025Review
- Evaluating the effects of pro-myelinating drugs on motor function and myelination in a zebrafish model of genetic leukoencephalopathy.Neuroscience letters · 2025Article
- Novel nerve regeneration assessment method using adult zebrafish with crush spinal cord injury.Journal of comparative physiology. A, Neuroethology, sensory, neural, and behavioral physiology · 2025Article
- A larval zebrafish model of traumatic brain injury: optimizing the dose of neurotrauma for discovery of treatments and aetiology.Biology open · 2025Article
- A robust paradigm for studying regeneration after traumatic spinal cord injury in zebrafish.Journal of neuroscience methods · 2024Article
- Drug screening in zebrafish larvae reveals inflammation-related modulators of secondary damage after spinal cord injury in mice.Theranostics · 2023Article
- Quantification of functional recovery in a larval zebrafish model of spinal cord injury.Journal of neuroscience research · 2022Article
- Apigenin inhibits fibrous scar formation after acute spinal cord injury through TGFβ/SMADs signaling pathway.CNS neuroscience & therapeutics · 2022Article
- Therapeutic Potential of CKD-504, a Novel Selective Histone Deacetylase 6 Inhibitor, in a Zebrafish Model of Neuromuscular Junction Disorders.Molecules and cells · 2022Article
- Regenerative neurogenesis: the integration of developmental, physiological and immune signals.Development (Cambridge, England) · 2022Article
- Uncovering the spectrum of adult zebrafish neural stem cell cycle regulators.Frontiers in cell and developmental biology · 2022Review
- Unique advantages of zebrafish larvae as a model for spinal cord regeneration.Frontiers in molecular neuroscience · 2022Review
- Review
- CRISPR gRNA phenotypic screening in zebrafish reveals pro-regenerative genes in spinal cord injury.PLoS genetics · 2021Article
- Shock waves promote spinal cord repair via TLR3.JCI insight · 2020Article
Corrections and comments
- Erratum issued
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Spinal cord injury (SCI) is a complex condition, with limited therapeutic options, that results in sensory and motor disabilities. To boost discovery of novel therapeutics, we designed a simple and efficient drug screening platform. This innovative approach allows to determine locomotor rescue properties of small molecules in a zebrafish (Danio rerio) larval spinal cord transection model. We validated our screening platform by showing that Riluzole and Minocycline, two molecules that are in clinical trials for SCI, promote rescue of the locomotor function of the transected larvae. Further validation of the platform was obtained through the blind identification of D-Cycloserine, a molecule scheduled to enter phase IV clinical trials for SCI. Importantly, we identified Tranexamic acid and further showed that this molecule maintains its locomotor recovery properties in a rodent female contusion model. Our screening platform, combined with drug repurposing, promises to propel the rapid translation of novel therapeutics to improve SCI recovery in humans.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.